Trial · NCT00521014
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
NCT00521014, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2015-12-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma. Trials, record NCT00521014. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00521014
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
- NCT number
- NCT00521014
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 14 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, sargramostim, carmustine, cytarabine, etoposide, melphalan, autologous hematopoietic stem cell transplantation
- First posted
- 2007-08-27
- Last updated
- 2015-12-22
- Results first posted
- 2015-12-22
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival Rate | up to 3 years | after autologous stem cell transplantation (ASCT). Disease progression is defined using International Workshop Criteria for non-Hodgkin lymphoma37 and is defined as: 1. ≥ 50% increase in products of diameters of any previously identified abnormal node or nodule AND/OR 2. appearance of any new lesions |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival Rate | up to 3 years | years | MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival Rate | Relapsed Follicular Lymphoma Patients | 1.759 | Full Range 0.47 to 2.3 | years |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Relapsed Follicular Lymphoma Patients | 14 | |
| Overall Study | COMPLETED | Relapsed Follicular Lymphoma Patients | 13 | |
| Overall Study | NOT COMPLETED | Relapsed Follicular Lymphoma Patients | 1 |
Source ClinicalTrials.gov
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Blood and lymphatic system disorders | Relapsed Follicular Lymphoma Patients | 5 | 13 | 5 |
| other | AST, SGOT | Blood and lymphatic system disorders | Relapsed Follicular Lymphoma Patients | 2 | 13 | 2 |
| other | Albumin, low (hypoalbuminemia) | Metabolism and nutrition disorders | Relapsed Follicular Lymphoma Patients | 1 | 13 | 1 |
| other | Alkaline phosphatase | Metabolism and nutrition disorders | Relapsed Follicular Lymphoma Patients | 1 | 13 | 1 |
| other | Amylase | Blood and lymphatic system disorders | Relapsed Follicular Lymphoma Patients | 1 | 13 | 1 |
| other | Bilirubin (hyperbilirubinemia) | Metabolism and nutrition disorders | Relapsed Follicular Lymphoma Patients | 3 | 13 | 3 |
| other | Creatinine | Metabolism and nutrition disorders | Relapsed Follicular Lymphoma Patients | 1 | 13 | 1 |
| other | Glucose, high (hyperglycemia) | Metabolism and nutrition disorders | Relapsed Follicular Lymphoma Patients | 6 | 13 | 6 |
| other | Hemoglobin | Blood and lymphatic system disorders | Relapsed Follicular Lymphoma Patients | 13 | 13 | 13 |
| other | Leukocytes (total WBC) | Blood and lymphatic system disorders | Relapsed Follicular Lymphoma Patients | 13 | 13 | 13 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Relapsed Follicular Lymphoma Patients | ||
| Total, other adverse events | Relapsed Follicular Lymphoma Patients | 13 | 13 |
| Total, serious adverse events | Relapsed Follicular Lymphoma Patients | 2 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | Rudin, Charles M. | SLOAN-KETTERING INST CAN RESEARCH | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00521014
GET https://conductscience.org/api/trials/v1/NCT00521014/registered